Infection Innovative Medicines, AstraZeneca R&D Boston, Waltham, MA 02451, USA. bolin.geng@astrazeneca.com
Abstract:
An SAR survey at the C-6 benzoxazinone position of a novel scaffold which inhibits bacterial type IIa topoisomerase demonstrates that a range of small electron donating groups (EDG) and electron withdrawing groups (EWG) are tolerated for antibacterial activity. Cyano was identified as a preferred substituent that affords good antibacterial potency while minimizing hERG cardiac channel activity.